EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Interações medicamentosas relativas ao tratamento de tuberculose: uma revisão de literatura

Camila Dias da Silva Sobral, Rita Catarina Medeiros Sousa

Revista ft · 08.08.2026 · 30 (161) · 01-14

DOI: 10.69849/pafgz239 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Revista ft, online erschienen am 08.08.2026. Verfasst von Camila Dias da Silva Sobral und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Tuberculosis remains a major cause of mortality worldwide, with a high prevalence in several Brazilian cities, particularly among populations with comorbidities who use medications with the potential to interact with those commonly prescribed for tuberculosis treatment.

Objective

To describe the main drug interactions associated with antituberculosis medications by analyzing their pharmacological mechanisms, clinical implications, and therapeutic management strategies in both general and specific populations.

Methods

This narrative, descriptive literature review was conducted using the PubMed and BVS/MEDLINE databases. The final sample comprised 21 studies, of which 18 were published within the last five years and 3 were published more than 10 years ago but were included because of their scientific relevance. Studies were selected using the descriptors “tuberculosis,” “treatment,” and “drug interaction.” Data were synthesized through thematic content analysis.

Results

Rifampicin was identified as the primary agent responsible for pharmacokinetic drug interactions due to its potent induction of CYP3A, CYP2C, and P-glycoprotein, substantially reducing exposure to antiretroviral agents (including integrase and protease inhibitors), hormonal contraceptives, and hormone replacement therapies. Although isoniazid exhibits inhibitory effects on CYP2C9 and CYP2C19 enzymes, the enzyme-inducing effect of rifampicin predominates during combination therapy. Clinical management requires specific dose adjustments, such as doubling the dose of dolutegravir, as well as close monitoring for overlapping toxicities, including an increased risk of hepatotoxicity, neurotoxicity, and QT interval prolongation in patients receiving polypharmacy regimens. Gastrointestinal interactions with antacids were also found to impair the bioavailability of isoniazid and fluoroquinolones. A common clinical situation currently requiring adjustment of the RHZE regimen is the concomitant treatment of fungal infections, such as histoplasmosis and sporotrichosis, with itraconazole.

Conclusion

Drug interactions in tuberculosis treatment pose significant challenges to therapeutic efficacy and patient safety, particularly in the presence of comorbidities. Individualized therapeutic management, based on dose adjustment and careful monitoring of adverse events, is essential for improving treatment adherence and reducing the development of bacterial resistance.

Zitieren

APA

Sobral, C. D. D. S., & Sousa, R. C. M. (2026). Interações medicamentosas relativas ao tratamento de tuberculose: uma revisão de literatura. Revista ft, 30(161), 01-14. https://doi.org/10.69849/pafgz239

Vancouver

Sobral CDDS, Sousa RCM. Interações medicamentosas relativas ao tratamento de tuberculose: uma revisão de literatura. Revista ft. 2026;30(161):01-14. doi:10.69849/pafgz239

BibTeX
@article{Sobral2026,
  author = {Sobral, Camila Dias da Silva and Sousa, Rita Catarina Medeiros},
  title = {Interações medicamentosas relativas ao tratamento de tuberculose: uma revisão de literatura},
  journal = {Revista ft},
  year = {2026},
  volume = {30},
  number = {161},
  pages = {01--14},
  doi = {10.69849/pafgz239}
}
Kostenlos starten →